Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mothaffar F Rimawi

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Future Oncology (London, England)|May 12, 2023
Margetuximab in HER2-positive metastatic breast cancerWilliam J Gradishar, Ruth O'Regan, Mothaffar F Rimawi, et al.
Nature Reviews. Clinical Oncology|December 15, 2019
Towards personalized treatment for early stage HER2-positive breast cancerKristina Goutsouliak, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, et al.
Cancer|January 19, 2010
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesMothaffar F Rimawi, Priya B Shetty, Heidi L Weiss, et al.
Advances in Experimental Medicine and Biology|January 17, 2025
HER2-Positive Breast Cancer Treatment and ResistanceJamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutierrez, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|February 27, 2010
Self-blame, self-forgiveness, and spirituality in breast cancer survivors in a public sector settingLois C Friedman, Catherine R Barber, Jenny Chang, et al.
Breast (Edinburgh, Scotland)|July 9, 2017
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistanceJamunarani Veeraraghavan, Carmine De Angelis, Jorge S Reis-Filho, et al.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|April 16, 2013
Predictors of post-mastectomy reconstruction in an underserved populationErik M Wolfswinkel, Santiago N Lopez, William M Weathers, et al.
Breast Cancer Research and Treatment|February 21, 2014
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistanceGladys Morrison, Xiaoyong Fu, Martin Shea, et al.
JCO Oncology Practice|May 19, 2023
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast CancerHope S Rugo, Christine L Crossno, Yaron B Gesthalter, et al.
Cancer Medicine|June 3, 2021
Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy aloneJason A Mouabbi, Momal Chand, Ishaq A Asghar, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Future Oncology (London, England)|May 12, 2023
Margetuximab in HER2-positive metastatic breast cancerWilliam J Gradishar, Ruth O'Regan, Mothaffar F Rimawi, et al.
Nature Reviews. Clinical Oncology|December 15, 2019
Towards personalized treatment for early stage HER2-positive breast cancerKristina Goutsouliak, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, et al.
Cancer|January 19, 2010
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesMothaffar F Rimawi, Priya B Shetty, Heidi L Weiss, et al.
Advances in Experimental Medicine and Biology|January 17, 2025
HER2-Positive Breast Cancer Treatment and ResistanceJamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutierrez, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|February 27, 2010
Self-blame, self-forgiveness, and spirituality in breast cancer survivors in a public sector settingLois C Friedman, Catherine R Barber, Jenny Chang, et al.
Breast (Edinburgh, Scotland)|July 9, 2017
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistanceJamunarani Veeraraghavan, Carmine De Angelis, Jorge S Reis-Filho, et al.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|April 16, 2013
Predictors of post-mastectomy reconstruction in an underserved populationErik M Wolfswinkel, Santiago N Lopez, William M Weathers, et al.
Breast Cancer Research and Treatment|February 21, 2014
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistanceGladys Morrison, Xiaoyong Fu, Martin Shea, et al.
JCO Oncology Practice|May 19, 2023
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast CancerHope S Rugo, Christine L Crossno, Yaron B Gesthalter, et al.
Cancer Medicine|June 3, 2021
Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy aloneJason A Mouabbi, Momal Chand, Ishaq A Asghar, et al.
Pageof 8